Mabwell (Shanghai) Bioscience Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS18
PHASE 3 / 2-35
RECRUITING12
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO0%
Delay Index: of 8 active trials registered more than a year ago, 0 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Mabwell (Shanghai) Bioscience Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| 9MW1911 NCT06175351 |
P1/2 | Active, not recruiting | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 80 | 2025-09-30 |
| 9MW2821 NCT06947226 |
P1/2 | Not yet recruiting | Solid Tumors | 188 | 2026-04 |
| 9MW2821 NCT06823427 |
P2 | Recruiting | Urothelial Carcinoma; Urothelial Carcinoma Bladder | 60 | 2026-06 |
| 9MW2821 NCT06492005 |
P2 | Recruiting | Triple-Negative Breast Cancer | 160 | 2026-07 |
| 9MW2821 NCT06196736 |
P3 | Recruiting | Advanced Urothelial Carcinoma | 432 | 2026-09 (-4 mo) |
| 9MW2921 NCT05990452 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 261 | 2026-09-01 |
| 9MW3811 Injection NCT07576608 |
P2 | Recruiting | Scar | 30 | 2026-12 |
| 9MW2821 NCT06079112 |
P1/2 | Recruiting | Advanced Urothelial Carcinoma | 100 | 2026-12-31 |
| 9MW2821+other anticancer therapy NCT06926998 |
P1/2 | Not yet recruiting | Gynecological Malignancies | 260 | 2027-05-01 |
| 7MW4911 NCT07265622 |
P1/2 | Recruiting | Solid Tumors | 200 | 2027-07 |
| 7MW4911 NCT07216560 |
P1/2 | Recruiting | GI Cancers | 200 | 2027-07 |
| 9MW2821 NCT06592326 |
P3 | Recruiting | Urothelial Carcinoma | 460 | 2027-09 |
| 9MW2821 NCT07556848 |
P3 | Not yet recruiting | Locally Advanced or Metastatic Triple-negative Breast Cancer | 356 | 2027-12 |
| 9MW1911 NCT07292714 |
P2 | Recruiting | Chronic Obstructive Pulmonary Disease COPD | 360 | 2027-12 |
| 9MW2821 NCT06692166 |
P3 | Recruiting | Cervical Cancer | 420 | 2027-12-09 |
| 7MW3711 NCT07466160 |
P1/2 | Recruiting | Solid Tumor | 280 | 2027-12-31 |
| 9MW2821 NCT07314723 |
P2 | Recruiting | Urothelial Carcinoma | 90 | 2027-12-31 |
| 7MW3711 NCT07831863 |
P3 | Not yet recruiting | Lung Squamous Cell Carcinoma | 600 | 2029-03 |